Compare Capital One Financial Corp. (COF) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs Pfizer Inc — how do they compare? Capital One Financial Corp. trades at $219.96 (market cap $134.45B), while Pfizer Inc trades at $26.26 (market cap $151.73B). The key difference: Capital One Financial Corp. and Pfizer Inc are close in size by market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| COF | PFE | |
|---|---|---|
Market Cap | $134.45B | $151.73B |
Sector | Financials | Health |
52-Week High | $257.94 | $28.56 |
52-Week Low | $176.10 | $23.60 |
Dividend Yield | 1.46% | 6.46% |
Volume | — | 29,869,932 |
Enterprise Value | — | $203.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $218.97, up 0.56% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81, while revenue growth accelerated to $53.43B in 2025. The Discover integration is on track, targeting $2.5B in synergies by late 2027, supporting double-digit EPS growth projections.
The outlook is positive, driven by strong card growth, technology advantages, and merger synergies, but risks include integration execution, credit loss provisions, and macroeconomic sensitivity. With a P/E of 12.07 and 63% analyst buy ratings, the stock offers value if Discover benefits materialize as planned.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
